(702) 683-8946

Monday - Friday 9am to 5pm

triangle
ad1

http://crweworld.com/assets/images/ad/buy_a_domain.png

Buy and register domain names online from CRWE Domains. Web hosting, spam-free email, web marketing, secure SSL Certificates and more

www.crwedomains.com

ad2

http://crweworld.com/assets/images/ad/ad4.png

Place Your Ad Here! Advertise your business online on CRWE WORLD. Your Company, product, or service in front of the world!

Contact Us: contact@crweworld.com

www.CRWEWorld.com

ad3

http://crweworld.com/assets/img/crwe_info.png

CRWE Info ( CRWE.Info ) provides news and updates about Crown Equity Holdings Inc. and the CRWE World platform

www.crwe.info

ad4

http://crweworld.com/assets/images/ad/submit_a_press_release.jpg

Submit Your Press Release/News to the CRWE WORLD Network for $14.95! Increase Visibility, Boost Your Business

www.CRWEPressRelease.com

ad5

http://crweworld.com/assets/images/ad/Pathology_Laboratories.png

Quest Diagnostics Inc. (NYSE:DGX) offers the most extensive clinical testing network in the U.S. The Company's extensive test menu includes routine biological testing; complex and specialized molecular and gene-based testing, and anatomic pathology testing. These services primarily help identify disease or risk factors for disease and predict and monitor response to treatment.

www.QuestDiagnostics.com






19 Result: Prostate Cancer

Nymox's New Phase 3 Long-Term U.S. Results For Prostate Enlargement Drug Fexapotide Show

August 29th, 2016

1. Dramatic Decrease in Prostate Cancer and 2. Major Reduction in Need For BPH Prostate Surgery HASBROUCK HEIGHTS, N.J. / CRWE PRESS RELEASE / August 29, 2016 - Nymox Pharmaceutical Corporation (NASDAQ:NYMX) lead drug fexapotide which has been . Read more

ANI Pharmaceuticals Announces FDA Approval and Immediate Launch of Nilutamide Tablets, the First Generic Competitor to Nilandron(R)

July 18th, 2016

BAUDETTE, Minnesota / CRWE PRESS RELEASE / July 18, 2016 - ANI Pharmaceuticals, Inc. (“ANI”) (Nasdaq: ANIP) today announced that it has received approval from the U.S. Food and Drug Administration (“FDA”) of the Abbreviated Ne. Read more

Aeterna Zentaris Commences Promotional Activities for APIFINY(R) Prostate Cancer Blood Test

February 23rd, 2016

Charleston, South Carolina / CRWEPRESSRELEASE / February 23, 2016 – Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the “Company”) today announced that it has started promoting APIFINY®, the only cancer specific, non-PSA bl. Read more

NW Bio Issues Statement on Adverse Market Conditions And NW Bio Stock Decline

January 08th, 2016

Sees Impact of Global Market Concerns; Reiterates Encouraging Clinical Data BETHESDA, MD / CRWEPRESSRELEASE / January 8, 2016 – Northwest Biotherapeutics (NASDAQ: NWBO) (“NW Bio”), a U.S. biotechnology company develop. Read more

Oasmia Pharmaceutical's Next Generation Anti-cancer Drug Docecal Approved for Clinical Trials

December 07th, 2015

Oasmia Pharmaceutical’s nanoparticle and water soluble, docetaxel-based drug Docecal is scheduled to enter clinical pivotal trials and begin patient recruitment in January 2016. Uppsala, Sweden / CRWEPRESSRELEASE / December 7, 2015 - Oasmia . Read more

Aeterna Zentaris Affirms Fundamental Strength of Business

November 25th, 2015

Quebec City, Canada / CRWEPRESSRELEASE / November 25, 2015 – Aeterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the “Company”), affirms that its business and prospects remain fundamentally strong and highlights the following developmen. Read more

Preclinical Studies Justify Mode of Delivery and Dosing Regimen for Anisina

November 10th, 2015

Intravenous Anisina drug product identified Efficacy in a preclinical model of neuroblastoma as monotherapy and in combination using IV delivery is retained Anisina safety assessment program has commenced Fort Lauderdale FL / CRWEPRESSREL. Read more

Affimed Presents Data on Potency of NK- and T-cell EGFRvIII TandAbs at SITC

November 06th, 2015

NK- and T-cell TandAbs Demonstrate Similar Robust Potency Heidelberg, Germany / CRWEPRESSRELEASE / November 6, 2015 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage biopharmaceutical company developing highly targeted cancer immunotherapies, . Read more

SeeThruEquity Issues Update on Pressure BioSciences (OTCQB: PBIO) Highlighting Robust Growth in 2015 and Recent Above Market Equity Offering

August 03rd, 2015

NEW YORK, NY / CRWEPRESSRELEASE / August 3, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has issued an update on Pressure BioSciences, In. Read more

Pressure BioSciences (PBIO) Showing Significant Potential for Continued Growth

July 30th, 2015

PHOENIX, AZ / CRWEPRESSRELEASE / July 30, 2015 / Months ago Uptick looked at Pressure BioSciences (OTCMKTS:PBIO), following the release of a Zacks Small-Cap report from April on the company and the award of over a million dollars in grant funding. . Read more

SeeThruEquity Initiates Coverage on MetaStat, Inc. with a Price Target of $1.23

June 25th, 2015

NEW YORK, NY / CRWEPRESSRELEASE / June 25, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has initiated coverage of MetaStat, Inc. (OTCMK. Read more

SeeThruEquity Initiates Coverage on VolitionRX Ltd. (NYSE MKT: VNRX) with Price Target of $6.70

March 09th, 2015

NEW YORK, NY / CRWEPRESSRELEASE / March 9, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has initiated coverage of VolitionRX Ltd. (NYSEMK. Read more

Pacific Therapeutics CEO Provides Corporate Update To Shareholders

January 08th, 2015

VANCOUVER, BC / CRWEPRESSRELEASE / January 8, 2015 / Pacific Therapeutics Ltd. (CNSX:PT) (OTCBB:PCFTF) (1P3.F) (the "Company")("Pacific") is a clinical stage Specialty Pharmaceutical Company using proprietary technologies to repurpose and reformulate. Read more

IsoRay's Cesium-131 Therapy Stops Brain Cancers from Recurring in Treated Locations Where Previous Conventional Treatments Failed

December 01st, 2014

World-Renowned Barrow Neurological Institute Releases Dramatic Brain Study Findings RICHLAND, WA / CRWEPRESSRELEASE / December 1, 2014 / IsoRay Inc. (NYSEMKT: ISR), a medical technology company and innovator in brachytherapy and medical isotope ap. Read more

Advaxis, Inc. – “From Two Checkpoint Inhibitor Development Agreements to Two IND Filings in Four Months – A Special Thanks…”

November 24th, 2014

New York, NY / CRWE Press Release / November 24, 2014 / Advaxis, Inc. (NASDAQ: ADXS) today published a new blog post on The Chairman’s Blog, written by the Company’s CEO, Daniel J. O’Connor. TheChairmansBlog.com is an exclusive onli. Read more

Load More Content